No Data
OS Therapies Reports Positive Preclinical Data for Ovarian Cancer Treatment | NYSE-A:OSTX
Express News | Os Therapies Inc: Strong Safety Profile for Fra-H With No Loss of Bodyweight as Compared With Control in Animal Models
Express News | Os Therapies Inc: Strong Efficacy for Fra-H in KB and Igrov-1 Mouse Models of Ovarian Cancer
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (TADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
EF Hutton Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $21
No Data
No Data
